Current Report Filing (8-k)
June 29 2021 - 7:07AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June
29, 2021
SYNTHETIC BIOLOGICS, INC.
(Exact name of registrant as specified in its charter)
Nevada
|
|
001-12584
|
|
13-3808303
|
(State or other jurisdiction of incorporation)
|
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
9605 Medical Center Drive, Suite 270
Rockville, MD 20850
(Address of principal executive offices and zip
code)
Registrant’s telephone number, including
area code: (301) 417-4364
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, par value $0.001 per share
|
SYN
|
NYSE American
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01
Regulation FD Disclosure.
On June 29, 2021, Synthetic
Biologics, Inc. (the “Company”) issued a press release announcing that that patient dosing
and observation has been completed in its Phase 1, open label, single-ascending dose (SAD) clinical trial of SYN-020 intestinal alkaline
phosphatase (IAP). The Phase 1 SAD study enrolled 24 healthy adult volunteers into four cohorts with SYN-020 given orally as single doses
ranging from 5 mg to 150 mg daily. Analyses of preliminary data demonstrated that SYN-020 maintained a favorable safety profile, was well
tolerated at all dose levels and no adverse events were attributed to the study drug. No serious adverse events were reported.
A second Phase 1 clinical trial intended to evaluate the safety, tolerability and biodistribution of multiple-ascending
doses (MAD) of SYN-020 in healthy volunteers is expected to commence during the third quarter of 2021. Topline results from this clinical
trial are anticipated during the second quarter of 2022. Both Phase 1 SAD and MAD studies are intended to support the development of SYN-020
in multiple potential clinical indications, including celiac disease, nonalcoholic fatty liver disease, radiation enteropathy, and indications
to treat and prevent metabolic and inflammatory disorders associated with aging, which are supported by the Company’s collaboration
with Massachusetts General Hospital.
A copy of the press release
is furnished as Exhibit 99.1 to this Report on Form 8-K. The information contained in the press release is being furnished to the Securities
and Exchange Commission (the “Commission”) and shall not be deemed incorporated by reference into any of the Registrant’s
registration statements or other filings with the Commission.
The information in this Item
7.01, and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section
or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with
the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general
incorporation language in such filing.
Item 8.01 Other Events
On June 29, 2021, the Company
announced that that patient dosing and observation has been completed in its Phase 1, open label, SAD
clinical trial of SYN-020 intestinal alkaline phosphatase (IAP). The Phase 1 SAD study enrolled 24 healthy adult volunteers into four
cohorts with SYN-020 given orally as single doses ranging from 5 mg to 150 mg daily. Analyses of preliminary data demonstrated that SYN-020
maintained a favorable safety profile, was well tolerated at all dose levels and no adverse events were attributed to the study drug.
No serious adverse events were reported. A second Phase 1 clinical trial intended to evaluate the
safety, tolerability and biodistribution of multiple-ascending doses of SYN-020 in healthy volunteers is expected to commence during the
third quarter of 2021. Topline results from this clinical trial are anticipated during the second quarter of 2022. Both Phase 1 SAD and
MAD studies are intended to support the development of SYN-020 in multiple potential clinical indications, including celiac disease, nonalcoholic
fatty liver disease, radiation enteropathy, and indications to treat and prevent metabolic and inflammatory disorders associated with
aging, which are supported by the Company’s collaboration with Massachusetts General Hospital.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is furnished with this Current
Report on Form 8-K:
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
SYNTHETIC BIOLOGICS, INC.
|
|
|
|
|
|
By:
|
/s/ Steven A. Shallcross
|
|
|
Name:
|
Steven A. Shallcross
|
|
|
Title:
|
Chief Executive Officer
and Chief Financial Officer
|
Synthetic Biologics (AMEX:SYN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Synthetic Biologics (AMEX:SYN)
Historical Stock Chart
From Sep 2023 to Sep 2024